NAFLD (Non-alcoholic Fatty Liver Disease)
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders characterized by excessive lipid accumulation in hepatocytes. Each stage of the disease spectrum has distinctive histopathological characteristics. The beginning stages include simple hepatic steatosis, which is characterized by fat droplet accumulation in hepatocytes and this is usually benign and asymptomatic. The disease may progress further to non-alcoholic steatohepatitis (NASH), which may include hepatocellular injury, ballooning (i.e. cellular swelling) and/or inflammation. If left unchecked, NASH can lead to fibrosis, cirrhosis, and ultimately HCC, thus affecting overall liver function.
In spite of the enormous amount of research in the field of NAFLD/NASH in the past decade, the precise mechanisms underlying the development of NAFLD and its progression to NASH have not been completely elucidated, including its link to metabolic syndrome, requiring additional studies and models to elucidate its pathophysiology. Because of its growing worldwide prevalence, various animal models that mirror both the pathophysiology and the histopathology of each stage of NAFLD/NASH are available. Certain dietary approaches can drive NAFLD/NASH in rodent models to mimic human disease and produce different severities of disease along the NAFLD spectrum, and depending on the dietary manipulations, likely work by unique mechanisms. This is essential in determining how the disease progresses, and also helps in evaluating different therapeutic approaches towards the treatment of specific stages of NAFLD. To read more, see our Product Literature
Our Latest Publication
Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models